Get an alert when MINA (HOLDINGS) LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Cash

£67k

-92.2% lowest in 3 filed years

Net assets

-£8.6m

-2% lowest in 3 filed years

Employees

30

-9.1% lowest in 3 filed years

Profit before tax

-£5.6m

+43.6% highest in 3 filed years

Watchouts

Facts from the Companies House register and the latest accounts — not a rating

Accounts

3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31

Metric Trend 2023-12-312024-12-312025-12-31 Δ vs prior
Turnover £4,678,682£1,550,529£1,770,724 +14.2%
Operating profit -£7,803,032-£8,545,120-£4,271,572 +50%
Profit before tax -£9,033,302-£9,866,127-£5,564,009 +43.6%
Net profit -£7,506,260-£8,548,649-£4,342,885 +49.2%
Cash £5,470,015£861,193£67,423 -92.2%
Total assets less current liabilities £2,770,260-£3,455,141-£5,135,194 -48.6%
Net assets -£3,563,210-£8,469,165-£8,637,710 -2%
Equity -£3,563,210
Average employees 343330 -9.1%
Wages £3,459,726£2,431,364£2,492,663 +2.5%
Directors' remuneration £721,822£644,001£509,201 -20.9%

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show . About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-312025-12-31
Operating margin -166.8%
Net margin -160.4%
Return on capital employed -281.7%
Gearing (liabilities / total assets) 133.5%247.8%264.8%
Current ratio 1.24x0.52x0.43x
Interest cover -6.30x-6.40x-3.30x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
IFRS
Reporting scope
Consolidated group
Abridged
Yes — abridged accounts (limited disclosure)
Auditor
Ernst & Young LLP
Audit opinion
Unaudited (audit-exempt)
Going concern
Material uncertainty disclosed

“At the date of the issuance of these financial statements, the Company estimates that it has approximately 11 months of cash on hand and expected to be received shortly, and therefore it does not have sufficient to fund its operations for the next 12 months to 30 June 2027. While the Company anticipates the achievement of certain milestone payments relating to its ongoing collaborations, these cannot be certain.”

Group structure

  1. MINA (HOLDINGS) LIMITED · parent
    1. MINA Therapeutics Limited 100% · England · Development of new treatments for medical conditions
    2. MINA Alpha Limited 100% · England · Development of new treatments for medical conditions
    3. MINA Beta Limited 100% · England · Development of new treatments for medical conditions
    4. MINA Therapeutics Denmark ApS 100% · Denmark · Development of new treatments for medical conditions

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

7 active · 7 resigned

Name Role Appointed Born Nationality
BAINS, Peter James Jonathan Director 2014-12-17 Jul 1957 British
BISCHOFBERGER, Norbert Wolfgang, Dr. Director 2025-03-17 Jan 1956 American
CLEMENT-DAVIES, Susan Elizabeth Director 2022-01-01 Jul 1962 British
GALANTINE-HELLER, Stephanie Director 2025-02-17 Mar 1983 French
HABIB, Robert Sebastian Director 2014-11-03 Nov 1985 British
KOPPLE, Robert Charles Director 2014-12-17 Mar 1944 American
LECHLER, Robert Ian, Sir Director 2022-01-01 Dec 1951 British
Show 7 resigned officers
Name Role Appointed Resigned
COHEN, Yael Gruenbaum, Dr. Director 2025-02-17 2025-11-10
HABIB, Nagy, Professor Director 2014-12-17 2023-03-01
JOHNSON, Kieran Roy Darren Director 2019-05-15 2022-10-13
ROSHWALB, Gur-Arye, Dr. Director 2020-08-04 2024-07-10
SCHINDEL, Yair Chaim, Dr Director 2024-07-29 2025-02-17
WOOD, Christopher Barry, Prof Director 2014-12-17 2023-03-01
OVAL NOMINEES LIMITED Corporate Director 2014-11-03 2014-11-03

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Stephanie Galantine-Heller Individual Shares 25–50%, Voting 25–50% 2025-02-17 Active
Robert Charles Kopple Individual Shares 25–50%, Voting 25–50% 2025-02-17 Active
Dr Yair Chaim Schindel Individual Shares 75–100%, Voting 75–100%, Appoints directors 2024-09-08 Ceased 2025-02-17
Heptares Therapeutics Limited Corporate entity Voting 25–50% 2018-11-29 Ceased 2020-08-04
Sosei R&D Limited Corporate entity Voting 25–50% 2017-05-02 Ceased 2018-11-29

Filing timeline

Last 20 of 123 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2025-03-07 MA Memorandum articles
  • 2025-03-07 RESOLUTIONS Resolution
Date Type Category Description
2026-07-25 AA accounts Accounts with accounts type group
2026-03-10 SH01 capital Capital allotment shares PDF
2026-01-05 CH01 officers Change person director company with change date PDF
2025-12-27 PSC04 persons-with-significant-control Change to a person with significant control PDF
2025-12-24 SH01 capital Capital allotment shares PDF
2025-12-24 CH01 officers Change person director company with change date PDF
2025-12-24 CH01 officers Change person director company with change date PDF
2025-12-24 PSC04 persons-with-significant-control Change to a person with significant control PDF
2025-12-18 TM01 officers Termination director company with name termination date PDF
2025-11-04 CS01 confirmation-statement Confirmation statement with updates PDF
2025-07-28 AA accounts Accounts with accounts type group
2025-06-26 SH01 capital Capital allotment shares PDF
2025-05-28 AA accounts Accounts with accounts type total exemption full
2025-03-25 PSC01 persons-with-significant-control Notification of a person with significant control PDF
2025-03-25 PSC01 persons-with-significant-control Notification of a person with significant control PDF
2025-03-21 AP01 officers Appoint person director company with name date PDF
2025-03-21 PSC09 persons-with-significant-control Withdrawal of a person with significant control statement PDF
2025-03-07 MA incorporation Memorandum articles
2025-03-07 RESOLUTIONS resolution Resolution
2025-03-05 PSC08 persons-with-significant-control Notification of a person with significant control statement PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
10

last 12 months

Capital events
3

last 24 months

Officers appointed
0

last 12 months

Officers resigned
1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page